Obexelimab is under clinical development by Zenas BioPharma (USA) and currently in Phase II for Multiple Sclerosis. According to GlobalData, Phase II drugs for Multiple Sclerosis have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Obexelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Obexelimab overview
Obexelimab (XmAb-5871) is under development for the treatment and prevention of IgG4-related disease (IgG4-RD), a fibro-inflammatory autoimmune disorder, autoimmune hemolytic anemia, systemic lupus erythematosus and multiple sclerosis. It is administered by intravenous, subcutaneous and subdermal routes. It is a humanized monoclonal antibody that targets the antigen CD19 and co-engages CD32b (Fc gammaRIIb). The drug candidate is developed based on XmAb technology. It was also under development for moderate to severe rheumatoid arthritis.
It was also under development for the treatment of unspecified indication.
Zenas BioPharma (USA) overview
Zenas BioPharma (USA) (Zenas) is a biopharmaceutical company that provides the development and commercialization of immunology-based therapies. The company pipeline product includes Obexelimab (ZB012), ZB002, ZB004, ZB001/011 and ZB005. Its product pipeline indications include IgG4-related disease, warm autoimmune haemolytic anaemia (wAIHA), thyroid eye disease and autoimmune disorders. Zenas collaborates with business partners such as Xencor, Inc., Viridian Therapeutics, Inc., and Dianthus Therapeutics to drive operational excellence and deliver potentially transformative therapies. Zenas is headquartered in Waltham, Massachusetts, the US.
For a complete picture of Obexelimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
